Literature DB >> 30001166

Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.

Krissie Lenting1,2, Mohammed Khurshed3, Tom H Peeters4, Corina N A M van den Heuvel1,2, Sanne A M van Lith2, Tessa de Bitter2, Wiljan Hendriks5, Paul N Span6, Remco J Molenaar3, Dennis Botman3, Kiek Verrijp2, Arend Heerschap4, Mark Ter Laan7, Benno Kusters2, Anne van Ewijk1, Martijn A Huynen8, Cornelis J F van Noorden3, William P J Leenders1,2.   

Abstract

Diffuse gliomas often carry point mutations in isocitrate dehydrogenase ( IDH1mut), resulting in metabolic stress. Although IDHmut gliomas are difficult to culture in vitro, they thrive in the brain via diffuse infiltration, suggesting brain-specific tumor-stroma interactions that can compensate for IDH-1 deficits. To elucidate the metabolic adjustments in clinical IDHmut gliomas that contribute to their malignancy, we applied a recently developed method of targeted quantitative RNA next-generation sequencing to 66 clinical gliomas and relevant orthotopic glioma xenografts, with and without the endogenous IDH-1R132H mutation. Datasets were analyzed in R using Manhattan plots to calculate distance between expression profiles, Ward's method to perform unsupervised agglomerative clustering, and the Mann Whitney U test and Fisher's exact tests for supervised group analyses. The significance of transcriptome data was investigated by protein analysis, in situ enzymatic activity mapping, and in vivo magnetic resonance spectroscopy of orthotopic IDH1mut- and IDHwt-glioma xenografts. Gene set enrichment analyses of clinical IDH1mut gliomas strongly suggest a role for catabolism of lactate and the neurotransmitter glutamate, whereas, in IDHwt gliomas, processing of glucose and glutamine are the predominant metabolic pathways. Further evidence of the differential metabolic activity in these cancers comes from in situ enzymatic mapping studies and preclinical in vivo magnetic resonance spectroscopy imaging. Our data support an evolutionary model in which IDHmut glioma cells exist in symbiosis with supportive neuronal cells and astrocytes as suppliers of glutamate and lactate, possibly explaining the diffuse nature of these cancers. The dependency on glutamate and lactate opens the way for novel approaches in the treatment of IDHmut gliomas.-Lenting, K., Khurshed, M., Peeters, T. H., van den Heuvel, C. N. A. M., van Lith, S. A. M., de Bitter, T., Hendriks, W., Span, P. N., Molenaar, R. J., Botman, D., Verrijp, K., Heerschap, A., ter Laan, M., Kusters, B., van Ewijk, A., Huynen, M. A., van Noorden, C. J. F., Leenders, W. P. J. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.

Entities:  

Keywords:  anaplerosis; diffuse infiltration; glycolysis; metabolism; neurotransmitters

Mesh:

Substances:

Year:  2018        PMID: 30001166     DOI: 10.1096/fj.201800907RR

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  17 in total

1.  Extracellular glutamate and IDH1R132H inhibitor promote glioma growth by boosting redox potential.

Authors:  Patricia D B Tiburcio; David L Gillespie; Randy L Jensen; L Eric Huang
Journal:  J Neurooncol       Date:  2020-02-04       Impact factor: 4.130

2.  Crucial Role of RLIP76 in Promoting Glycolysis and Tumorigenesis by Stabilization of HIF-1α in Glioma Cells Under Hypoxia.

Authors:  Qi Wang; Chi Zhang; Junle Zhu; Lei Zhang; Huairui Chen; Jun Qian; Chun Luo
Journal:  Mol Neurobiol       Date:  2022-08-23       Impact factor: 5.682

3.  The influence of cystathionine on neurochemical quantification in brain tumor in vivo MR spectroscopy.

Authors:  Francesca Branzoli; Dinesh K Deelchand; Roberto Liserre; Pietro Luigi Poliani; Lucia Nichelli; Marc Sanson; Stéphane Lehéricy; Małgorzata Marjańska
Journal:  Magn Reson Med       Date:  2022-04-05       Impact factor: 3.737

4.  IDH1R132H is intrinsically tumor-suppressive but functionally attenuated by the glutamate-rich cerebral environment.

Authors:  Patricia D B Tiburcio; Bing Xiao; Yi Chai; Sydney Asper; Sheryl R Tripp; David L Gillespie; Randy L Jensen; L Eric Huang
Journal:  Oncotarget       Date:  2018-10-12

5.  GABA, glutamine, glutamate oxidation and succinic semialdehyde dehydrogenase expression in human gliomas.

Authors:  Zoltán Hujber; Gergő Horváth; Gábor Petővári; Ildikó Krencz; Titanilla Dankó; Katalin Mészáros; Hajnalka Rajnai; Norbert Szoboszlai; William P J Leenders; András Jeney; László Tretter; Anna Sebestyén
Journal:  J Exp Clin Cancer Res       Date:  2018-11-07

6.  Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate.

Authors:  Tom H Peeters; Krissie Lenting; Vincent Breukels; Sanne A M van Lith; Corina N A M van den Heuvel; Remco Molenaar; Arno van Rooij; Ron Wevers; Paul N Span; Arend Heerschap; William P J Leenders
Journal:  Cancer Metab       Date:  2019-05-20

7.  Mapping actionable pathways and mutations in brain tumours using targeted RNA next generation sequencing.

Authors:  Krissie Lenting; Corina N A M van den Heuvel; Anne van Ewijk; Duaa ElMelik; Remco de Boer; Elizabeth Tindall; Ge Wei; Benno Kusters; Maarten Te Dorsthorst; Mark Ter Laan; Martijn A Huynen; William P Leenders
Journal:  Acta Neuropathol Commun       Date:  2019-11-20       Impact factor: 7.801

8.  A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors.

Authors:  Mohammed Khurshed; Remco J Molenaar; Myra E van Linde; Ron A Mathôt; Eduard A Struys; Tom van Wezel; Cornelis J F van Noorden; Heinz-Josef Klümpen; Judith V M G Bovée; Johanna W Wilmink
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

9.  Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles.

Authors:  Nils Ludwig; Aparna Rao; Poorva Sandlesh; Saigopalakrishna S Yerneni; Alexander D Swain; Kristin M Bullock; Kim M Hansen; Xiaoran Zhang; Emade Jaman; Jordan Allen; Katharine Krueger; Chang-Sook Hong; William A Banks; Theresa L Whiteside; Nduka M Amankulor
Journal:  Neuro Oncol       Date:  2022-02-01       Impact factor: 13.029

Review 10.  Shedding New Light on Cancer Metabolism: A Metabolic Tightrope Between Life and Death.

Authors:  Matthias Läsche; Günter Emons; Carsten Gründker
Journal:  Front Oncol       Date:  2020-03-31       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.